Janssen Sciences Ireland Unlimited Company

Matthew M Rankin

Chichi Huang

Shamina M Rangwala

Xiefan Lin-Schmidt

Serena Nelson

Shannon Mullican

Jennifer Furman

Songmao Zheng

Xiefan Lin-schmidt

Serena M Nelson

Provided herein are method of using GLP1-GDF15 fusion proteins for reducing food intake, preventing, treating or ameliorating diseases and disorders, such as obesity, type 2 diabetes, the metabolic syndrome, insulin resistance, and dyslipidemia, among others, the fusion protein comprising a GLP1 or GLP1 variant peptide, a first linker peptide, a serum albumin protein, a second linker peptide, and a GDF15 protein.

Glucagon like peptide 1 (GLP1)-growth differentiation factor 15 (GDF15) fusion proteins and uses thereof

Provided herein are GLP1-GDF15 fusion proteins comprising a GLP1 or GLP1 variant peptide, a first linker peptide, a serum albumin protein, a second linker peptide, and a GDF15 protein.

Growing community of inventors

Spring House, PA, United States of America

Matthew M Rankin